From January 1, 2024 to March 31, 2024, the company has repurchased 312,170 shares, representing 0.29% for $298.09 million. With this, the company has completed the repurchase of 2,253,328 shares, representing 2.11% for $1,769.01 million under the buyback announced on February 3, 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
994 USD | +0.68% | +0.95% | +13.17% |
05-20 | Regeneron, Sanofi Disclose Positive Results for Lung Disease Treatment Candidate | MT |
05-20 | Jefferies Raises Regeneron Pharmaceuticals' Price Target to $1,125 From $1,115 | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+13.17% | 107B | |
+8.63% | 115B | |
-12.76% | 22.31B | |
-3.99% | 21.6B | |
-7.19% | 18.23B | |
-39.93% | 17.62B | |
+6.67% | 14.26B | |
+33.90% | 12.37B | |
-28.60% | 8.28B | |
+17.28% | 8.26B |
- Stock Market
- Equities
- REGN Stock
- News Regeneron Pharmaceuticals, Inc.
- Tranche Update on Regeneron Pharmaceuticals, Inc.'s Equity Buyback Plan announced on February 3, 2023.